Publications

• Martini R, Davis MB. The DARC side of genetics in cancer: Breast cancer disparities. Am J Hum Genet. 2024 Jul 11;111(7):1261-1264. doi: 10.1016/j.ajhg.2024.05.011. PMID: 38996469.
  ​
• Newman LA, Chen Y, Martini R, Demaria S, Formenti S, Elemento O, Davis MB. Tumor-Associated Lymphocytes and Breast Cancer Survival in Black and White Women. JAMA Surg. 2024 Jun 1;159(6):712-714. doi: 10.1001/jamasurg.2023.8024. PMID: 38446467; PMCID: PMC10918575.
  ​
• Johnson JR, Martini RN, Yuan YC, Woods-Burnham L, Walker M, Ortiz-Hernandez GL, Kobeissy F, Galloway D, Gaddy A, Oguejiofor C, Allen B, Lewis D, Davis MB, Kimbro KS, Yates CC, Murphy AB, Kittles RA. 1,25-Dihydroxyvitamin D3 Suppresses Prognostic Survival Biomarkers Associated with Cell Cycle and Actin Organization in a Non-Malignant African American Prostate Cell Line. Biology(Basel). 2024 May 15;13(5):346. doi: 10.3390/biology13050346. PMID: 38785827; PMCID: PMC11118023.
  ​
• Casolino R, Beer PA, Chakravarty D, Davis MB, Malapelle U, Mazzarella L, Normanno N, Pauli C, Subbiah V, Turnbull C, Westphalen CB, Biankin AV. Interpreting and integrating genomic tests results in clinical cancer care: Overview and practical guidance. CA Cancer J Clin. 2024 May-Jun;74(3):264-285. doi: 10.3322/caac.21825. Epub 2024 Jan 4. PMID: 38174605.
  ​
• Madorsky Rowdo FP, Xiao G, Khramtsova GF, Nguyen J, Martini R, Stonaker B, Boateng R, Oppong JK, Adjei EK, Awuah B, Kyei I, Aitpillah FS, Adinku MO, Ankomah K, Osei-Bonsu EB, Gyan KK, Altorki NK, Cheng E, Ginter PS, Hoda S, Newman L, Elemento O, Olopade OI, Davis MB, Martin ML, Bargonetti J. Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment. Cancer Lett. 2024 Mar 1;584:216608. doi: 10.1016/j.canlet.2024.216608. Epub 2024 Jan 9. PMID: 38199587; PMCID: PMC10922546.
  ​​
• Noch EK, Palma LN, Yim I, Bullen N, Qiu Y, Ravichandran H, Kim J, Rendeiro A, Davis MB, Elemento O, Pisapia DJ, Zhai K, LeKaye HC, Koutcher JA, Wen PY, Ligon KL, Cantley LC. Insulin feedback is a targetable resistance mechanism of PI3K inhibition in glioblastoma. Neuro Oncol. 2023 Dec 8;25(12):2165-2176. doi: 10.1093/neuonc/noad117. PMID: 37399061; PMCID: PMC10708938.
  ​​
• Telesford KM, Smith C, Mettlen M, Davis MB, Cowell L, Kittles R, Vartanian T, Monson N. Neuron-binding antibody responses are associated with Black ethnicity in multiple sclerosis during natalizumab treatment. Brain Commun. 2023 Aug 14;5(4):fcad218. doi: 10.1093/braincomms/fcad218. PMID: 37601407; PMCID: PMC10433937.